McGuire Investment Group LLC Boosts Position in Johnson & Johnson (NYSE:JNJ)

McGuire Investment Group LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 26,785 shares of the company’s stock after acquiring an additional 171 shares during the quarter. McGuire Investment Group LLC’s holdings in Johnson & Johnson were worth $3,767,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Chelsea Counsel Co. lifted its holdings in shares of Johnson & Johnson by 3.9% in the fourth quarter. Chelsea Counsel Co. now owns 45,344 shares of the company’s stock worth $6,614,000 after buying an additional 1,693 shares in the last quarter. Sector Gamma AS lifted its holdings in shares of Johnson & Johnson by 0.3% in the first quarter. Sector Gamma AS now owns 117,532 shares of the company’s stock worth $15,412,000 after buying an additional 303 shares in the last quarter. Tradewinds Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 1.3% in the first quarter. Tradewinds Capital Management LLC now owns 7,602 shares of the company’s stock worth $997,000 after buying an additional 101 shares in the last quarter. Pennsylvania Trust Co lifted its holdings in shares of Johnson & Johnson by 1.3% in the first quarter. Pennsylvania Trust Co now owns 409,496 shares of the company’s stock worth $53,698,000 after buying an additional 5,413 shares in the last quarter. Finally, Private Asset Management Inc. lifted its holdings in shares of Johnson & Johnson by 0.5% in the second quarter. Private Asset Management Inc. now owns 93,956 shares of the company’s stock worth $13,213,000 after buying an additional 425 shares in the last quarter. 68.44% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Wells Fargo & Co upgraded shares of Johnson & Johnson to a “hold” rating in a research report on Wednesday, April 22nd. UBS Group cut shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $163.00 to $160.00 in a research report on Tuesday, April 28th. Cantor Fitzgerald restated a “buy” rating and issued a $168.00 price target on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Finally, Bank of America upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $150.00 to $175.00 in a research report on Wednesday, April 22nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the stock. Johnson & Johnson has an average rating of “Buy” and an average price target of $162.93.

JNJ stock traded up $1.50 during mid-day trading on Tuesday, reaching $146.71. 1,166,517 shares of the stock traded hands, compared to its average volume of 6,522,271. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.05 and a current ratio of 1.31. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The stock has a market capitalization of $375.09 billion, a PE ratio of 19.21, a PEG ratio of 3.10 and a beta of 0.69. The business has a 50-day moving average price of $143.57 and a two-hundred day moving average price of $143.88.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The business had revenue of $20.69 billion for the quarter, compared to analysts’ expectations of $19.48 billion. During the same quarter in the previous year, the business posted $2.10 earnings per share. The business’s revenue was up 3.3% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 7.7 earnings per share for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Understanding Average Daily Trade Volume

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.